FDA
-
-
-
-
-
-
-
IceCure reports ProSense cryoablation growth in Brazil after FDA nod
-
-
-
-
-
-
-
IceCure Medical reports kidney cancer study results at medical conference
-
-
-
-
-
-
-
IceCure Appoints Meir Peleg as Chief Financial Officer
-
-
-
-
-
-
-
IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense®, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation
-
-
-
-
-
-
-
IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales
-
-
-
-
-
-
-
IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer
-
-
-
-
-
-
-
IceCure Medical Ltd. (ICCM) PT Raised to $2.50 at H.C. Wainwright
-
327,956 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

